3Mon·

$MEDP (+0.09%) Reports Q3 2024

Sales: 533M vs 541M expected (Miss)

EBIT: 112M vs 101M expected (Beat)

Income: 96M vs 90M expected (Beat)


  • New Business Awards 533M (Miss) leads to Book-To-Bill of 1.00 down from 1.2-1.3 Range YoY


Outlook for FY24:

Rev: 2.11B vs 2.14B expected (Miss)

EBITDA: 460M vs 450M expected (Beat)

Income: 381M vs 371M expected (Beat)


Expectations were apparently very high. The company is more profitable than expected with less growth. Book-To-Bill is approaching 1. A value below 1 signals a shrinking business, but the backlog is almost 3B, which makes MEDP booked out for a year. So there is still enough time to generate new growth

9
25 Comments

profile image
a big fall
immediately moves to my watchlist 😅
how do you see medpace now?
1
profile image
@Memo0606 I am already invested and would like to add to my holdings, but would wait and see.
profile image
@SemiGrowth all right then I'll wait
do you think it will go down even further or would you wait for the bottom to form?
1
profile image
1
profile image
@Memo0606
Memo my friend,
what about
$UFPT
profile image
@Tenbagger2024 i haven't given up on the stock my friend but it's still too expensive :((
I prefer to buy ufpt
profile image
@Tenbagger2024 according to aktienfinder, for example, 90% too expensive 😝
1
profile image
@Tenbagger2024 when would you go in at the earliest?
profile image
Ufp Has already corrected the last few weeks.
profile image
@Memo0606
Think when you are at the 200-day line.
profile image
@Tenbagger2024 yes but is that enough for a first purchase my friend
I don't think so
View all 13 further answers
profile image
The last earnings were already below expectations here.
I think some competitors have also joined the market, which should put pressure on margins.
Join the conversation